Care Options
EHV-1 Vaccine for Horses: What to Know and Where to Start
Yes, vaccines are available for horses to reduce EHV-1 respiratory disease and abortion risk, but no licensed vaccine is labeled to prevent its neurological form.
Key takeaways
Yes, vaccines are available for horses to reduce EHV-1 respiratory disease and abortion risk, but no licensed vaccine is labeled to prevent its neurological form.
- The equine herpesvirus type 1 (EHV-1) vaccine helps protect horses against certain effects of equine herpesvirus infection.
- EHV-1 can cause respiratory illness, pregnancy loss, newborn foal deaths and neurological complications.
- Vaccination is an important part of prevention, particularly for horses that travel, attend competitions, live in breeding facilities or regularly encounter other horses.
- However, vaccination does not replace testing, isolation and good stable hygiene.
- Understanding what the vaccine protects against, when horses may need it and what it cannot prevent helps owners make informed decisions about equine health.
What the Vaccine Is Designed to Do
The EHV-1 vaccine is designed to reduce the risk and severity of certain illnesses caused by equine herpesvirus type 1.
It is a preventive measure rather than a treatment for an existing infection.
EHV-1 belongs to a family of viruses that affect horses. It can cause several different conditions:
• Respiratory disease: Infection of the upper respiratory tract, sometimes called rhinopneumonitis.
• Reproductive disease: Infection during pregnancy can lead to abortion or stillbirth.
• Neurological disease: EHV-1 can affect the nervous system, causing equine herpesvirus myeloencephalopathy (EHM).
• Newborn foal disease: Infection can cause severe illness or death in newborn foals.
EHV-1 and equine herpesvirus type 4 (EHV-4) are closely related but distinct viruses. Both can cause respiratory disease, while EHV-1 is particularly associated with pregnancy loss and neurological complications.
There are different types of EHV vaccines available in the United States:
Inactivated vaccines: These contain killed virus material. Some are licensed to help prevent respiratory disease, while others have additional labeling for preventing EHV-1-related abortion in pregnant mares.
Modified-live vaccines: These contain a weakened form of the virus. A licensed modified-live EHV-1 vaccine is available to help prevent respiratory disease in healthy horses.
Some products combine protection against EHV-1 and EHV-4. The appropriate product depends on the horse's health, reproductive status and exposure risk.
The American Association of Equine Practitioners (AAEP) recommends using vaccination as part of a broader disease-prevention program. The intended benefit includes reducing disease severity and viral shedding within horse populations.
How EHV-1 Spreads and Why Vaccination Helps
EHV-1 spreads between horses through respiratory secretions, direct contact and contaminated objects.
An infected horse can release the virus through its nose, allowing other horses to become exposed.
Common transmission routes include:
• Nose-to-nose contact between horses.
• Exposure to respiratory droplets and nasal discharge.
• Shared feed buckets, water containers and grooming equipment.
• Contaminated saddles, tack, clothing and stable equipment.
• Contact with aborted fetuses, placentas and fluids from an infected pregnancy.
The virus can spread even when a horse does not appear seriously ill.
One important characteristic of EHV-1 is latency. After the initial infection, the virus can remain inactive inside a horse for much of its life. Stress, transportation, changes in management and other challenges can contribute to viral reactivation.
A horse with a latent infection may begin shedding the virus again without showing obvious signs of illness. This creates difficulties for horse owners and stable managers trying to prevent transmission.
Vaccination helps the horse's immune system recognize the virus and respond to exposure. Depending on the product, vaccination can reduce respiratory disease severity, nasal shedding and the amount of virus circulating in the bloodstream.
Reducing viral shedding can help limit transmission within a group of horses. Vaccination therefore benefits individual animals and can contribute to herd-level disease control.
However, vaccination does not eliminate latent infection or guarantee that an exposed horse will not become infected. Good hygiene, isolation and monitoring remain important parts of prevention.
What Owners May See in Real Life
An EHV-1 vaccination program usually forms part of a horse's routine preventive veterinary care.
The horse's age, previous vaccination history, breeding status and exposure to other horses help determine the appropriate schedule.
A veterinarian may recommend vaccination for horses that:
• Regularly attend competitions or horse shows.
• Travel between different farms and facilities.
• Live in breeding operations.
• Have contact with pregnant mares.
• Are younger horses entering training or living in groups with frequent horse movement.
Owners should understand the difference between a vaccine reaction and signs of an actual EHV-1 infection.
Signs following vaccination
Some horses experience temporary changes after receiving a vaccine. These may include soreness around the injection site, mild swelling, a temporary increase in temperature or reduced appetite.
These reactions are different from the clinical signs of an EHV-1 infection. Their presence does not automatically mean the vaccine has failed.
Signs of EHV-1 infection
An infected horse may develop:
• Fever.
• Nasal discharge.
• Coughing.
• Depression or unusual tiredness.
• Reduced appetite.
• Swollen lymph nodes.
• Swelling in the limbs.
• Abortion in a pregnant mare.
The neurological form can cause additional problems, including hind-limb weakness, poor coordination, difficulty urinating and reduced tail function.
In severe cases, a horse may become unable to stand. Neurological complications can affect the bladder, hindquarters and other parts of the nervous system.
Veterinarians use clinical examinations and laboratory testing to investigate suspected infections. Polymerase chain reaction (PCR) testing of nasal swabs and blood samples can help identify EHV-1.
Clinical signs alone cannot reliably distinguish EHV-1 from other respiratory infections. Testing helps determine whether the virus is responsible for the illness.
Sudden hind-limb weakness, difficulty standing or loss of bladder control requires urgent veterinary attention.
Risks and Limitations of the EHV-1 Vaccine
The main limitation of an EHV-1 vaccine is that it does not provide complete protection against every form of the disease.
Neurological protection is not established
No currently licensed EHV-1 vaccine carries a label claim for preventing equine herpesvirus myeloencephalopathy.
Vaccination may reduce viral shedding and other measures associated with infection, but owners should not assume that a vaccinated horse is protected against EHM.
This limitation is particularly important during outbreaks involving neurological cases. Biosecurity and isolation remain essential even when horses have received their recommended vaccines.
Protection is not guaranteed
Vaccinated horses can still become infected. Available products do not cover every possible viral strain, and the immune response varies between individual animals.
Vaccination also does not remove latent EHV-1 from a horse's body. An animal that carries the virus can potentially reactivate and shed it later.
Possible vaccine reactions
Most expected reactions are temporary, but vaccination carries some risk of adverse effects.
Potential reactions include:
• Muscle soreness.
• Swelling around the injection site.
• Temporary fever.
• Reduced appetite.
• Lethargy.
• More serious systemic reactions, including hives, colic and anaphylaxis.
Horses with compromised immune systems, existing illnesses or previous severe vaccine reactions may require additional assessment before vaccination. Pregnancy and concurrent medication use can also affect the risk-benefit assessment.
The AAEP recommends that vaccination take place under veterinary supervision because serious reactions, although uncommon, can require medical intervention.
Difficulty breathing, collapse or a severe allergic reaction after vaccination requires emergency veterinary care.
What to Do About EHV-1 Vaccination
Developing an appropriate vaccination program starts with understanding the horse's individual risk.
There is no single schedule that applies to every horse.
The AAEP provides recommendations based on age, reproductive status, previous vaccination and exposure.
Foals and young horses
The AAEP recommends a primary series of three EHV-1 vaccinations for foals.
The recommended series begins at 4 to 6 months of age. The first and second vaccinations are separated by 4 weeks, with the third given at 10 to 12 months of age.
Young horses may need continued boosters because immunity following vaccination can be relatively short-lived.
Adult horses
Adult horses with no previous vaccination history, or an unknown history, may need a primary series of two or three doses, depending on the vaccine product.
The AAEP recommends a 4-week interval between doses.
Previously vaccinated adult horses do not all need the same booster schedule. Six-month revaccination is recommended for certain higher-risk groups, including:
• Horses younger than 5 years.
• Horses on breeding farms or in contact with pregnant mares.
• Horses at facilities with frequent movement of animals.
• Performance and show horses in high-exposure environments.
Frequent vaccination is generally not indicated for every mature, non-breeding horse because clinical respiratory disease is less common in horses over 4 years of age.
Pregnant mares
Pregnant mares have specific vaccination requirements because EHV-1 can cause pregnancy loss.
For abortion prevention, the AAEP recommends an inactivated EHV-1 vaccine licensed for this purpose during the fifth, seventh and ninth months of pregnancy.
Some veterinary programs also include vaccination during the third month of pregnancy or at breeding.
An additional inactivated EHV-1/EHV-4 vaccination 4 to 6 weeks before foaling is commonly used to increase antibodies in colostrum and support protection against respiratory disease in newborn foals.
The product selected for a pregnant mare must be appropriate for its intended reproductive use.
Combine vaccination with biosecurity
Vaccination is only one part of an effective prevention plan.
Horse owners and stable managers can reduce exposure through practical measures:
1. Isolate new horses and animals returning from competitions or other facilities for at least 21 days.
2. Monitor horses for fever and respiratory symptoms.
3. Avoid sharing grooming supplies, tack, feed buckets and water containers.
4. Clean and disinfect frequently used equipment and stable surfaces.
5. Limit unnecessary contact between horses from different facilities.
6. Keep pregnant mares separate from groups with increased exposure risk.
7. Maintain accurate vaccination and health records.
During a confirmed EHM incident, vaccination is not recommended as an emergency response. Post-vaccination fever can complicate quarantine monitoring, and vaccination is not a substitute for isolation or disease-control measures.
The attending veterinarian and relevant state animal health officials should coordinate the response to an outbreak.
Where to Get Help
An equine veterinarian is the main source of guidance for EHV-1 vaccination, diagnosis and disease prevention.
A veterinary practice can review vaccination records, assess exposure risks, select an appropriate vaccine and develop a schedule for individual horses or an entire stable.
Additional resources include:
• American Association of Equine Practitioners (AAEP): Provides equine vaccination guidelines and information about EHV-1 prevention.
• USDA Animal and Plant Health Inspection Service (APHIS): Provides equine herpesvirus information, disease-control guidance and access to accredited veterinarians.
• Equine Disease Communication Center (EDCC): Provides equine disease information, biosecurity resources and outbreak alerts.
If a horse develops fever, nasal discharge, coughing, limb swelling or reproductive complications, prompt veterinary assessment can help identify the cause.
Ask your veterinarian to review the horse's vaccination history, exposure risk and reproductive status before establishing or changing an EHV-1 vaccination program.
Early veterinary involvement and consistent biosecurity help protect individual horses and the wider equine population.
Frequently asked questions
Is there a vaccine for EHV-1 in horses?
Yes. Several EHV-1 vaccine options are available in the United States. They help reduce respiratory disease and, for specifically licensed products, the risk of EHV-1-related abortion. None is licensed to prevent the neurological form of the disease.
Does a positive EHV-1 blood antibody test mean a horse is infected?
Not necessarily. Antibodies can develop following vaccination or previous natural exposure, so a single antibody result cannot reliably confirm an active infection. PCR testing of appropriate samples is used to investigate suspected EHV infection.
Can humans catch EHV-1 from horses?
No. EHV-1 is an equine virus and does not pose a health risk to people. However, people can transfer contaminated respiratory secretions between horses through clothing, footwear and equipment, making hand hygiene and stable biosecurity important.
Can donkeys and mules receive the EHV-1 vaccine?
Vaccination information for donkeys, mules and other equids is more limited than for horses. The AAEP notes that there are limited data for these animals, so vaccination decisions should be made according to an individual veterinary assessment.
Editorial standards
Who wrote this guide
Written by VetWayfinder Editorial Team.
Every factual statement is tied to a cited source listed below. Report an error through the corrections page.
Sources
Each source supports at least one factual statement in this guide.
